CA3124220A1 - Derives d'oxopyridine substitues - Google Patents

Derives d'oxopyridine substitues Download PDF

Info

Publication number
CA3124220A1
CA3124220A1 CA3124220A CA3124220A CA3124220A1 CA 3124220 A1 CA3124220 A1 CA 3124220A1 CA 3124220 A CA3124220 A CA 3124220A CA 3124220 A CA3124220 A CA 3124220A CA 3124220 A1 CA3124220 A1 CA 3124220A1
Authority
CA
Canada
Prior art keywords
mmol
methyl
mixture
represents hydrogen
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3124220A
Other languages
English (en)
Inventor
Susanne Rohrig
Sebastian ESSIG
Pascal ELLERBROCK
Sonja Anlauf
Thomas Neubauer
Alexander Hillisch
Katharina MEIER
Stefan Heitmeier
Adrian Tersteegen
Martina Schafer
Jan Stampfuss
Dieter Lang
Hongping WANG
Zengqiang ZOU
Xianghai Meng
Kersten Matthias Gericke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Publication of CA3124220A1 publication Critical patent/CA3124220A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

L'invention concerne des dérivés d'oxopyridine substitués et des procédés pour leur préparation, ainsi que leur utilisation pour la préparation de médicaments pour le traitement et/ou la prophylaxie de maladies, en particulier de troubles vasculaires, de préférence de troubles thrombotiques ou thromboemboliques et/ou de complications thrombotiques ou thromboemboliques.
CA3124220A 2018-12-21 2019-12-18 Derives d'oxopyridine substitues Pending CA3124220A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2018122825 2018-12-21
CNPCT/CN2018/122825 2018-12-21
PCT/EP2019/085983 WO2020127504A1 (fr) 2018-12-21 2019-12-18 Dérivés d'oxopyridine substitués

Publications (1)

Publication Number Publication Date
CA3124220A1 true CA3124220A1 (fr) 2020-06-25

Family

ID=69143542

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3124220A Pending CA3124220A1 (fr) 2018-12-21 2019-12-18 Derives d'oxopyridine substitues

Country Status (22)

Country Link
EP (1) EP3898633A1 (fr)
JP (1) JP2022514303A (fr)
KR (1) KR20210106504A (fr)
CN (1) CN113474348A (fr)
AR (1) AR117435A1 (fr)
AU (1) AU2019407909B2 (fr)
BR (1) BR112021009435A2 (fr)
CA (1) CA3124220A1 (fr)
CL (1) CL2021001613A1 (fr)
CO (1) CO2021007908A2 (fr)
CR (1) CR20210342A (fr)
DO (1) DOP2021000128A (fr)
EA (1) EA202191764A1 (fr)
EC (1) ECSP21043895A (fr)
IL (1) IL283990A (fr)
JO (1) JOP20210161A1 (fr)
MA (1) MA54521A (fr)
MX (1) MX2021007508A (fr)
PE (1) PE20211790A1 (fr)
SG (1) SG11202104384PA (fr)
TW (1) TW202039510A (fr)
WO (1) WO2020127504A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3765452T3 (da) * 2018-03-15 2022-06-27 Bayer Ag Fremgangsmåde til fremstilling af to 4-{[(2s)-2-{4-[5-chlor-2-(1h-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2h)-yl}butanoyl]amino}-2-fluorbenzamidderivater
CN114105881B (zh) 2020-08-31 2024-01-26 沈阳海诺威医药科技有限公司 血小板聚集抑制剂及其制备方法和用途
CR20230431A (es) 2021-03-09 2023-10-27 Bayer Ag Formas de dosificación farmacéuticas que comprenden (4S)–24–cloro–4–etil–73–fluoro–35– metoxi–32,5–dioxo–14–(trifluorometil)–32H–6–aza–3(4,1)–piridina–1(1)–[1,2,3]triazola– 2(1,2),7(1) dibencenaheptafano–74–carboxamida
WO2022189280A1 (fr) 2021-03-09 2022-09-15 Bayer Aktiengesellschaft Solvates de (4s)-24-chloro-4-éthyl-73-fluoro-35-méthoxy-32,5-dioxo-14-(trifluoro-méthyl)-32 h-6- aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-dibenzenaheptaphane-74-carboxamide
US20240174633A1 (en) 2021-03-09 2024-05-30 Bayer Aktiengesellschaft Crystalline forms of (4s)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14-(trifluoro-methyl)-32h-6-aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-dibenzenaheptaphane-74-carboxamide
CN114560754A (zh) * 2022-02-25 2022-05-31 滁州学院 一种烷基醇的制备方法
CN116874469B (zh) * 2023-09-06 2023-11-10 成都施贝康生物医药科技有限公司 一种氧代吡啶类化合物、中间体及其制备方法和用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
DE102006032824A1 (de) * 2006-07-14 2008-01-17 Bayer Healthcare Ag Substituierte Indazole
EP2091947A2 (fr) 2006-12-20 2009-08-26 Takeda San Diego, Inc. Activateurs de glucokinase
EP2978425B1 (fr) 2013-03-27 2017-09-27 Merck Sharp & Dohme Corp. Inhibiteurs du facteur xia
TWI633089B (zh) 2013-03-28 2018-08-21 拜耳製藥股份有限公司 經取代的酮基吡啶衍生物
CN105555767B (zh) 2013-07-23 2018-03-23 拜耳制药股份公司 取代的氧代吡啶衍生物及其作为因子xia/血浆的用途
US9765070B2 (en) 2013-10-30 2017-09-19 Bayer Pharma Aktiengesellschaft Substituted oxopyridine derivatives
CN106687458B (zh) 2014-09-24 2020-10-27 拜耳制药股份公司 取代的氧代吡啶衍生物
WO2016046158A1 (fr) 2014-09-24 2016-03-31 Bayer Pharma Aktiengesellschaft Dérivés d'oxopyridine substitués
ES2716417T3 (es) 2014-09-24 2019-06-12 Bayer Pharma AG Derivados de oxopiridina sustituidos con acción antiinflamatoria y antitrombótica
EP3197891B1 (fr) * 2014-09-24 2018-11-21 Bayer Pharma Aktiengesellschaft Dérivés de pyridobenzazépine et de pyridobenzazocine inhibant le facteur xia
WO2016046156A1 (fr) 2014-09-24 2016-03-31 Bayer Pharma Aktiengesellschaft Dérivés d'oxopyridine substitués
WO2016046166A1 (fr) 2014-09-24 2016-03-31 Bayer Pharma Aktiengesellschaft Dérivés d'oxopyridine substitués
JP2018509426A (ja) * 2015-03-19 2018-04-05 バイエル ファーマ アクチエンゲゼルシャフト 血栓症の治療のための因子ＸＩａ阻害剤としてのオキソピリジン誘導体
JO3703B1 (ar) 2015-07-09 2021-01-31 Bayer Pharma AG مشتقات أوكسوبيريدين مستبدلة
WO2017037051A1 (fr) 2015-09-04 2017-03-09 Bayer Pharma Aktiengesellschaft Dérivés d'oxopyridine substitués

Also Published As

Publication number Publication date
CN113474348A (zh) 2021-10-01
CO2021007908A2 (es) 2021-07-19
MX2021007508A (es) 2021-08-05
BR112021009435A2 (pt) 2021-08-17
EP3898633A1 (fr) 2021-10-27
TW202039510A (zh) 2020-11-01
AR117435A1 (es) 2021-08-04
KR20210106504A (ko) 2021-08-30
AU2019407909A1 (en) 2021-05-27
JOP20210161A1 (ar) 2023-01-30
SG11202104384PA (en) 2021-05-28
JP2022514303A (ja) 2022-02-10
AU2019407909B2 (en) 2023-05-25
ECSP21043895A (es) 2021-07-30
EA202191764A1 (ru) 2021-10-22
CL2021001613A1 (es) 2021-12-03
IL283990A (en) 2021-07-29
DOP2021000128A (es) 2021-09-30
MA54521A (fr) 2022-03-30
PE20211790A1 (es) 2021-09-09
WO2020127504A1 (fr) 2020-06-25
CR20210342A (es) 2021-08-09

Similar Documents

Publication Publication Date Title
AU2019407909B2 (en) Substituted oxopyridine derivatives
US9765070B2 (en) Substituted oxopyridine derivatives
CN108026072B (zh) 取代的氧代吡啶衍生物
AU2014242971B2 (en) Substituted oxopyridine derivatives and use thereof in the treatment of cardiovascular disorders
US10138236B2 (en) Factor xia-inhibiting pyridobenzazepine and pyridobenzazocine derivatives
CN106687458B (zh) 取代的氧代吡啶衍生物
US10414731B2 (en) Substituted oxopyridine derivatives
US20180250280A1 (en) Substituted oxopyridine derivatives
CA2979937A1 (fr) Derives d'oxopyridine comme inhibiteurs du facteur xia pour le traitement de la thrombose
CA3123324A1 (fr) Derives d'oxopyridine substitues pour le traitement et/ou la prophylaxie de troubles thrombotiques ou thromboemboliques et/ou de complications thrombotiques ou thromboemboliques
US10077265B2 (en) Substituted oxopyridine derivatives
TW201808908A (zh) 因子XIa抑制劑
CA3124296A1 (fr) Derives d'oxopyridine substitues
EA044932B1 (ru) Замещенные оксопиридиновые производные
JP2016520111A (ja) 置換ベンゾキサゾール
JP2016520110A (ja) 置換ベンゾキサゾール
TW202320754A (zh) 經取代的ｓ－丙胺酸酯衍生物
JP2008512365A (ja) 第Ｘａ因子阻害物質として使用する、Ｎ−（１−（２，３−ジヒドロ−１Ｈ−インデン−５イル）−２−オキソ−３−ピロリジニル）−スルホンアミド誘導体